Study Reaffirms Low AF Stroke and Bleeding Rates – MM1701
Data from XAPASS – a prospective observational postauthorisation study, which enrolled more than 11 000 patients in Japan – confirmed low rates of both stroke and major bleeding in patients with non-valvular AF newly-initiated on rivaroxaban in routine clinical practice. These results were generally consistent with the Phase III J-ROCKET AF randomised clinical trial.
Modern Medicine – January 2017
